期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 28, 期 4, 页码 748-755出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2018.01.006
关键词
Monobactam; PBP-3; beta-Lactamases; Metallo-beta-lactamases; NDM-1; KPC; CRE; beta-Lactam; Antibiotic
Metallo-beta-lactamases (MBLs), such as New Delhi metallo-beta-lactamase (NDM-1) have spread world-wide and present a serious threat. Expression of MBLs confers resistance in Gram-negative bacteria to all classes of beta-lactam antibiotics, with the exception of monobactams, which are intrinsically stable to MBLs. However, existing first generation monobactam drugs like aztreonam have limited clinical utility against MBL-expressing strains because they are impacted by serine beta-lactamases (SBLs), which are often co-expressed in clinical isolates. Here, we optimized novel monobactams for stability against SBLs, which led to the identification of LYS228 (compound 31). LYS228 is potent in the presence of all classes of beta-lactamases and shows potent activity against carbapenem-resistant isolates of Enterobacteriaceae (CRE). (C) 2018 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据